The latest price target for AstraZeneca (NASDAQ:AZN) was reported by UBS on November 20, 2024. The analyst firm set a price target for $0.00 expecting AZN to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for AstraZeneca (NASDAQ:AZN) was provided by UBS, and AstraZeneca upgraded their neutral rating.

The last upgrade for AstraZeneca PLC happened on November 20, 2024 when UBS raised their price target to N/A. UBS previously had a sell for AstraZeneca PLC.

The last downgrade for AstraZeneca PLC happened on February 8, 2024 when Deutsche Bank changed their price target from N/A to N/A for AstraZeneca PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AstraZeneca, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AstraZeneca was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest AstraZeneca (AZN) rating was a upgraded with a price target of $0.00 to $0.00. The current price AstraZeneca (AZN) is trading at is $66.47, which is out of the analyst’s predicted range.